CA-ANDERSEN-GLOBAL
13.7.2024 16:43:35 CEST | Business Wire | Pressemeddelelse
Andersen Global har tilføjet værdiansættelseskapacitet i Afrika og styrket sin overordnede regionale dækning ved at tilknytte to nye samarbejdsvirksomheder – Nelson Thorpe Alonge i Nigeria og Valeo Capital i Sydafrika. Med disse tilføjelser markerer Andersen sine første udbud af værdiansættelsesservice i Afrika og og øger dermed virksomhedens udbud af global værdiansættelse i Nordamerika, Europa, Latinamerika, Mellemøsten og Asien.
Nelson Thorpe Alonge udbyder en komplet portefølje af værdiansættelse af aktiver, der dækker jord og bygninger, anlæg og udstyr, maritime aktiver, olie og gas, luftfart, ejendomsinvesteringer, ejendomsmæglervirksomhed, salg og opkøb, ejendoms- og facilitetsadministration samt rådgivning om ejendomsudstykning. Under ledelse af seniorpartner Victor Alonge betjener virksomheden selskaber, internationale agenturer, diplomatiske enheder, stater, statslige agenturer og personer med stor nettoformue.
"Kundernes succes og tilfredshed står i centrum af vores forretningsstrategi," siger Victor. "Vores samarbejde med Andersen Global er en milepæl for vores virksomhed og viser, at vi altid engagerer os maksimalt i forhold til vores kunder, når vi udvider vores virkeområde til at levere perfekte og omfattende værdiansættelsesløsninger globalt."
Valeo Capital er stiftet af de to partnere Riaan van Heerden og David Tosi og er en specialiseret virksomhed, der arbejder tæt sammen med kunder lige fra greenfieldvirksomheder til børsnoterede selskaber. Virksomheden yder omfattende virksomhedsfinansiering og -rådgivning, herunder fusioner og opkøb, BEE-ejerskabsstrukturering (black economic empowerment), værdiansættelse af virksomheder, due diligence og kapitalrejsning.
"Vi er stolte af den ressourcestyrke, pålidelighed og professionelle indsigt, vi giver til kunder og ønsker at fortsætte med at udvide vores udbud til kunder lokalt og globalt," siger Riaan. "Vores samarbejde med Andersen Global er en yderligere styrkelse af vores teams engagement i at yde klassens bedste service og fastholder vores konkurrencefordel i regionen."
Global Chairman og CEO for Andersen Mark L. Vorsatz siger: "Nelson Thorpe Alonge og Valeo Capital har konsekvent demonstreret deres forpligtelse på god forvaltning og kundeservice, og har skilt sig ud som førende på markedet. Både Nigeria og Sydafrika er som altid vigtige markeder, og virksomhedernes ekspertise er vigtig for vores globale ekspansionsstrategi og for at opfylde de skiftende værdiansættelseskrav fra kunder både regionalt og i udlandet."
Andersen Global er en international sammenslutning af juridisk adskilte og uafhængige medlemsvirksomheder, der består af skattejurister samt skatte- og værdiansættelseseksperter i hele verden. Andersen Global, der blev etableret i 2013 af den amerikanske medlemsvirksomhed Andersen Tax LLC, har nu mere end 17.000 eksperter i hele verden og en tilstedeværelse på over 475 lokaliteter gennem sine medlemsvirksomheder og samarbejdsvirksomheder.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20240711008688/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
